These contradictory findings stress the importance of further investigations to better understand the mechanism of action of different classes of CAIX inhibitors before being implemented as anti-cancer agents in combination with standard treatment modalities such as doxorubicin treatment. The gene discussed is CA9; the disease is cancer.